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Overproduction of parathyroid hormone-related protein (PTHRP) occurs in a high proportion of primary breast cancers (PBC) and is
strongly implicated in their metastatic spread to bone. Although the PTHRP-receptor (PTHRP-R) is often coexpressed with PTHRP
in PBC, its role in regulating breast cancer cell proliferation and metastases to bone remains unclear. The aims of this study were to
determine the expression of the PTHRP-R in breast cancer bone metastases (BM) and to investigate the effects of PTHRP-R
overexpression on breast cancer cell proliferation. PTHRP-R expression occurred in 85% (11 out of 13) of BM compared with 58%
(39 out of 67) of PBC. Median expression was higher (Po0.05) in BM compared with PBC. PTHRP increased cAMP accumulation
and DNA synthesis in MCF-7 cells stably overexpressing the PTHRP-R (MCF-7
WTR) but not in MCF-7
VEC control cells. The increase
in DNA synthesis was mimicked by the cAMP pathway activator forskolin. The receptor antagonist PTHRP7–34 reduced DNA
synthesis in MCF-7
WTR cells, but not MCF-7
VEC cells, indicating that receptor overexpression promotes autocrine PTHRP activity.
MCF-7
WTR cells showed increased mitogenic responsiveness to fetal calf serum and reduced doubling times. PTHRP induced weak
activation of ERK1 and ERK2 and potentiated their activation by serum growth factors. Collectively these results show that the
PTHRP-R is frequently expressed in breast cancer BM and indicate that receptor overexpression drives proliferation via autocrine
signals that are mediated via cAMP and ERK pathways.
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Parathyroid hormone-related protein (PTHRP) was first identified
as the causative factor in the paraneoplastic syndrome humoral
hypercalcaemia of malignancy (HHM) (Suva et al, 1987). The
amino-terminal region of PTHRP is similar to that in parathyroid
hormone (PTH) and both hormones share a common G protein-
coupled receptor, known as the PTH/PTHRP receptor (PTHRP-R).
In contrast to PTH, which is produced almost exclusively by the
parathyroid gland and circulates as an endocrine regulator of
calcium homeostasis, PTHRP has been found in almost every
tissue and acts via paracrine or autocrine mechanisms to regulate
development and cell growth and differentiation (reviewed in
Wysolmerski and Stewart, 1998).
Substantial evidence indicates that PTHRP is involved in
breast cancer progression. In particular, a number of studies
strongly implicate PTHRP as having a major role in the
preferential metastatic spread of breast cancers to the skeleton.
For example, compared to primary breast tumours and non-
skeletal metastases, PTHRP is more frequently expressed in
bone metastases (BM) (Powell et al, 1991). Moreover, expre-
ssion of PTHRP in primary tumours predicts the subse-
quent development of BM (Bundred et al, 1992; Bouizar et al,
1993) and correlates with poor prognosis (Yoshida et al,
2000). Tumour cells secreting PTHRP may be better able to
survive and proliferate in bone since localised production of
PTHRP by breast cancer cells in these sites has been shown to
promote osteolysis in a mouse model of skeletal metastasis (Guise
et al, 1996).
In contrast to the substantial body of evidence linking PTHRP to
breast cancer progression, much less is known about the role
played by the PTHRP-R. Several breast tumour cell lines express
the PTHRP-R and proliferate in response to PTHRP (Birch et al,
1995; Cataisson et al, 2000). Other studies have detected PTHRP-R
expression in primary tumours (Carron et al, 1997; Downey et al,
1997; Iezzoni et al, 1998). Moreover, PTHRP-R and ligand are
coexpressed in majority of these tumours supporting the idea that
there may be paracrine or autocrine mechanisms involving PTHRP
that are important for tumour progression. In support of this, we
recently found that coexpression of PTHRP-R and ligand in
primary breast cancers predicts poor patient prognosis (Linforth
et al, 2002).
Overexpression of PTHRP and its receptor in breast tumour
cells could also promote the growth of such cells in skeletal
metastases by stimulating their proliferation in an autocrine
fashion. To investigate this idea, we have set out to establish
whether breast cancer cells maintain or upregulate PTHRP-R
expression in these lesions by comparing the frequency and extent
of PTHRP-R expression in BM with that in primary breast cancers.
In consequence of our findings, we then characterised how
overexpression of the PTHRP-R in breast cancer cells influences
their proliferative responsiveness.
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Assessment of PTHRP-R expression in primary breast
cancers and skeletal metastases
Following ethical approval, samples of malignant breast carcinoma
tissue and BM were collected from patients undergoing surgery at
the South Manchester University Hospital. After surgical excision,
samples were removed from the tumour and snap frozen in liquid
nitrogen. Bone metastases were collected during surgery on
patients presenting with acute pathological fractured femurs
because of breast cancer, who underwent open reduction and
internal fixation of the fracture.
RNA was extracted from tissue samples using Trizolt (Invitro-
gen, Paisley, UK) in accordance with the manufacturer’s protocol.
RNA yield was quantitated by UV spectrophotometry and the
integrity verified on agarose gels. PCR analysis of PTHRP-R
expression was carried out following global amplification of
expressed genes by poly(A) PCR (Brady and Iscove, 1993; Al-
Taher et al, 2000). Direct comparison of mRNA expression levels
measured using this technique gave identical results to those
obtained using conventional RT–PCR or TaqMan real-time
quantitative PCR (Brady, unpublished data). For gene-specific
PCR, reactions, were carried out in a total volume of 22ml and
contained 1ng of poly(A) cDNA, 0.33mM each oligonucleotide PCR
primer, 0.5U Taq polymerase (Roche Biochemicals, Lewes, UK)
and 0.25mM dNTPs. PCR primers for the PTHRP-R were directed
towards the mRNA sequence within 300bp of the poly(A) addition
site, as described previously (Al-Taher et al, 2000): forward primer
(1734–1756) CCG CCT ACT GCC CAC TGC CAC CAC, reverse
primer (1973–1996) TCC ATC CAC TAT GTC AGC AGG TCC. The
reactions were carried out in a programmable thermocycler
(Techne PHC-3) using the following conditions: one cycle of
2min at 941C, then 25–35 cycles of 30s at 941C, 30s at 601C and
1min at 721C, and finally one cycle of 5min at 721C.
In order to quantify gene expression, PCR reaction products
were run on a 1% agarose gel alongside a series of standards
containing known amounts of PCR product DNA. These were
prepared by combining the gene-specific PCR products generated
from several reactions and diluting these to produce a series
containing a known amount of DNA molecules from 1.5 10
10 to
1.5 10
4ml
 1, as described (Al-Taher et al, 2000). Dilutions were
made using a solution of sonicated carrier lambda DNA.
Following agarose gel electrophoresis, gels were denatured in
1.5 M NaCl, 0.5 M NaOH for 45min and then neutralised with 1 M
NH4OH before blotting on to Hybond-N membrane (Amersham,
Bucks, UK). The membrane was then rinsed in sodium phosphate
buffer and prehybridized for 2h at 551C with denatured salmon
sperm DNA. Membranes were then hybridised at 551C overnight
with a
32P-labelled oligonucleotide probe directed to a specific
sequence within the PTHRP-R PCR product, as follows: (1852–
1875) GAC GAT GGG TTC CTC AAC GGC TCC. The membrane
was then washed, dried and exposed to X-ray film for 1–3 days. In
addition, the hybridised bands were quantified using a phosphor-
imager. The values for the DNA standards were used to construct a
standard curve from which values for the samples were read.
Samples falling out with the linear range of the standard curve
were resubjected to PCR using a modified number of amplification
cycles.
PTHRP-R cDNA constructs and generation of stable
transfected cell populations
Wild-type human PTHRP-R cDNA in pcDNA1 plasmid vectors
were generously provided by Dr E Schipani (Boston). The receptor
cDNA was excised and subcloned into pCIneo (Promega, South-
ampton, UK) vector. Insertion was confirmed by restriction
digestions using EcoR1 and XbaI, and by direct sequencing. To
generate cell lines stably expressing the PTHRP-R, MCF-7 cells
(obtained from the ATCC and grown in DMEM containing 10%
fetal calf serum (FCS) and 2mM glutamine) were transfected with
9mg of the receptor cDNA or with empty pCIneo vector as a
control using FuGene6 (Roche Biochemicals) according to the
manufacturer’s instructions. Following transfection, cells were
placed in a selection medium containing 0.5mgml
 1 G418
(Invitrogen). After approximately 2 weeks, during which the
medium was changed every 2 days, resistant cells were expanded
for analysis. Subcloning of transfected cells was not performed and
all of the experiments reported in this study were carried out using
the entire population of G418-resistant cells.
PTHRP-R expression by RT–PCR in transfected stable
lines
Total RNA was extracted from approximately 5 10
6 cells using
the RNeasy kit (Qiagen, Crawley, UK). RT–PCR was carried out
using the enhanced avian RT–PCR kit (Sigma) with the following
primers designed to amplify a 571bp fragment:
forward 50-AGGAACAGATCTTCCTGCTGCA-30;
reverse 50-TGCATGTGGATGTAGTTGCGCGT-30.
The reactions used 100ng RNA with primers at a final
concentration of 250nM in the presence of 3mM MgCl2. First
strand synthesis was conducted at 421C for 50min, followed by
denaturation at 941C for 2min. A total of 35 cycles of denaturation
(941C, 15s) and annealing (681C, 1min) were followed by
extension at 681C for 5min. Reaction products were run alongside
100bp size markers on 1% agarose gels containing ethidium
bromide and the resulting gel photographed under UV light.
Cyclic AMP (CAMP) assay
This was carried out using the cAMP binding protein competitive
assay as described previously (Yarwood et al, 1998). In brief, cells
in six-well plates were starved overnight in serum-free medium
prior to stimulation with factors as described. Perchloric acid
extracts were then prepared followed by neutralisation and
removal of precipitated material by centrifugation. Supernatants
were stored at  801C prior to the assay. Samples were assayed in
the presence of 0.1mCi [
3H]cAMP and 8mg cAMP binding protein
(Sigma) alongside a series of standard cAMP solutions. Following
binding to equilibrium (2–3h), unbound cAMP was precipitated
by the addition of activated charcoal suspension. The suspension
was centrifuged and an aliquot of the supernatant solution counted
on a scintillation counter. Results are expressed as picomoles of
cAMP formed per million cells.
Thymidine uptake assay
Cells were grown to approximately 80% confluence in 24-well
plates. Cells were starved for 24h in serum-free medium and then
test agents were added in fresh serum-free medium for a further
24h. In experiments testing the effects of PTHRP7–34, following
incubation in serum-free medium, cells were treated for a further
24h in fresh serum-free medium or in a medium containing 0.5%
serum. Cultures received additionally either drug vehicle (0.0001%
acetic acid) or PTHRP7–34 (1mM). During the final 4h 0.25mCi
[
3H]thymidine (ICN) was added. Cells were then washed three
times with PBS followed by the addition of 0.5ml ice-cold TCA
(20% wv
 1) for 1h. The cell precipitates were washed twice with
20% TCA, once with 95% ethanol, then dissolved in 0.25ml 1 M
NaOH and neutralised with an equal volume of 1M HCl. Aliquots
were counted on a scintillation counter.
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Cells were plated in quadruplicate at low density in a medium
containing 2% serum. Cell numbers were counted using a
haemocytometer every 24h for a total of 96h. The average time
taken for each cell population to double in number was then
calculated from the logarithmic phase of the growth curve.
Measurement of PTHRP secretion
PTHRP was measured using a two-site immunoradiometric assay
(IDS Ltd, Tyne and Wear, UK). Cells were plated in triplicate
(10000cellswell
 1) in a 48-well plate. After 72h, the medium was
changed to serum-free medium and the cells were incubated for
48h. The conditioned medium was then collected and immediately
assayed alongside a series of PTHRP standards (0–40pmol). To
allow for variations in growth rate (see Results), cells were
removed and counted. PTHRP accumulation was expressed as pico
moles produced by 10
6 cells over the 48h incubation period.
ERK activation
ERK activation was assessed by immunoblotting cell lysates with
antiphospho-ERK antibodies as described previously (Yarwood
et al, 1999). Briefly, cells were starved in serum-free medium
overnight and then stimulated in fresh medium with either EGF,
IGF-I or PTHRP1–34 at the concentrations and for the times
detailed in the figure legends. Lysates were prepared and
equivalent amounts of cellular protein (20mg) were run out on
12% SDS–PAGE gels. The samples were transferred to Hybond
ECL (Amersham Bioscience, Bucks, UK), which was then blocked
and probed with antiphospho-ERK antibodies (Cell Signalling
Technology, Hitchin, UK) at 1:2000 dilution. Immunoreactive
bands were visualised following HRP-linked secondary antibody
incubation and reaction of the blots with Supersignal West Pico
(Pierce, Warrington, UK). Identical samples were run in parallel
and immunoblotted with anti-ERK total antibodies (Santa Cruz,
CA, USA) to confirm equivalent sample loading.
RESULTS
In order to investigate the potential importance of PTHRP-
mediated autocrine actions in metastatic breast cancer cells, we
initially examined whether the PTHRP-R was expressed in skeletal
metastases. Expression was measured by semiquantitative RT–
PCR followed by Southern blotting and scanning densitometry.
The data, presented in Figure 1, show that the PTHRP-R is
detectable in around 58% (39 of 67) of the primary breast cancers
compared to 85% (11 of 13) of the BM. While this difference just
fails to reach statistical significance (P¼0.053, w
2 test), these
results indicate that the PTHRP-R is expressed more frequently in
BM. In addition, although expression levels varied considerably,
especially among the primary cancer samples, the median receptor
expression level was higher in the metastases samples compared to
the primary cancers (2818 (1189–7483) vs 299 (10–3000); median
and interquartile range (Po0.05; Mann–Whitney U-test))
(Figure 1).
Expression of the PTHRP-R in metastatic breast cancers
supports the idea that tumour cells within these lesions are
responsive to PTHRP. Based on previous reports, showing that
PTHRP can increase proliferation in some breast cancer cell lines,
we reasoned that overexpression of the receptor would increase
mitogenic responses of cells to PTHRP. To examine this, MCF-7
breast carcinoma cells were transfected with a cDNA encoding the
human PTHRP-R. Following transfection and selection, we
confirmed stable receptor expression by RT–PCR and by
measuring the response of these cells to PTHRP in terms of cAMP
generation. Stable populations of cells transfected with PTHRP-R
cDNA (MCF-7
WTR) expressed the receptor, whereas vector-
transfected cells (MCF-7
VEC) did not (Figure 2A). MCF-7
WTR cells
exhibited a Efive-fold increase in cAMP accumulation in response
to PTHRP1–34, whereas MCF-7
VEC cells showed little or no
responsiveness to PTHRP1–34 (Figure 2B). The response of both
cell types to forskolin, which directly activates adenylyl cyclase,
was virtually identical indicating that receptor transfection did not
affect the basic functioning of the cAMP generation system.
To investigate the effects of PTHRP-R overexpression on
mitogenesis, we first examined the effect of exogenously added
PTHRP on thymidine uptake, as a measure of cell cycle
progression. MCF-7
VEC cells were unresponsive to PTHRP1–34
administered at two different concentrations (Figure 3). By
contrast, MCF-7
WTR cells showed a significant increase in
thymidine uptake in response to PTHRP1–34 treatment. Exposure
of both cell types to 100nM forskolin resulted in quantitatively
similar increases in thymidine incorporation indicating that cAMP
signals a mitogenic response in these cells.
We next sought evidence for autocrine-mediated effects of
PTHRP on proliferation. Previous studies have shown that MCF-7
cells synthesise PTHRP mRNA (Birch et al, 1995) and secrete
PTHRP into the medium (Rong et al, 1999). To confirm these
findings, we measured PTHRP secretion in each cell type using a
sensitive two-site immunoradiometric assay. These assays revealed
that PTHRP was present in the conditioned medium and that the
degree of PTHRP production was similar in each cell type
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Figure 1 Expression of the PTHRP-R in primary breast cancers and BM. PTHRP-R expression was measured in 67 primary breast cancers and 13 bone
metastases by RT–PCR as described in Materials and Methods. Relative expression was quantified by Southern blotting of the agarose gels using a specific
32P-labelled probe followed by phosphorimaging, and related to a series of standards of known amounts of DNA corresponding to the PCR product. Owing
to the wide variation in receptor expression within the primary cancer samples data were log10 transformed for clarity.
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VEC: 1.6770.05pmol10
4cells
 148h
 1; MCF-7
WTR cells:
1.5870.06). Since MCF-7 cells produce PTHRP, overexpression
of the PTHRP-R may sensitise such cells to autocrine activity. To
test this further, we examined the effects of PTHRP7–34, which acts
as an antagonist of the PTHRP-R and blocks ligand-induced
receptor activation (Nagasaki et al, 1989). Figure 4 shows that
incubation of MCF-7
WTR cells, in either serum-free medium or
medium containing 0.5% serum, with PTHRP7–34 significantly
reduced thymidine incorporation by 18 and 36%, respectively. In
contrast, MCF-7
VEC cells were unaffected by treatment with
PTHRP7–34. These experiments demonstrate that overexpression
of the wild-type PTHRP-R alone, in the absence of any alterations
in PTHRP ligand production, is sufficient to confer autocrine
proliferative responsiveness to PTHRP.
We next examined whether overexpression of the PTHRP-R
affected the general mitogenic responsiveness of MCF-7 cells.
Exposure of previously starved cells to normal growth medium
containing 10% FCS led to increases in thymidine uptake that were
similar in MCF-7
VEC and MCF-7
WTR cells (data not shown).
However, when the cells were treated instead with a medium
containing 2% serum, significant differences in responsiveness
were revealed. Stimulation of MCF-7
WTR cells resulted in a
12279% increase in thymidine uptake compared with MCF-7
VEC
cells where the increase was 7879% (Table 1). Consistent with
their apparent increased mitogenic responsiveness to serum, the
MCF-7
WTR cells also exhibited a doubling time that was
significantly lower than that measured for MCF-7
VEC cells
(Table 1). These results suggest that overexpression of the
PTHRP-R increases the capacity of MCF-7 cells to respond to
mitogenic factors present in FCS.
The preceding data indicate that overexpression of the PTHRP-
R increases the mitogenic responsiveness of breast cancer cells not
only to endogenous and exogenous PTHRP but also to hetero-
logous serum-derived growth factors. To begin to explore the
intracellular mechanisms that might mediate these effects, we
elected to characterise the signalling pathways that mediate the
proliferative actions of PTHRP in MCF-7 cells. The PTHRP-R can
couple to multiple signalling systems, including Ca
2+/protein
kinase C, cAMP and Ras/ERK pathways (Carpio et al, 2001; Miao
et al, 2001). PTHRP did not induce Ca
2+ accumulation in MCF-7
cells (data not shown) in agreement with a previous report (Birch
et al, 1995), making it unlikely that this pathway contributes to the
mitogenic actions of PTHRP. We attempted to address directly
whether cAMP signals were required for the proliferative actions of
PTHRP using H89, a selective inhibitor of cAMP-dependent
protein kinase. However, at concentrations required to block
PKA (5–10mM) this agent caused extensive cell detachment and
apoptosis within a few hours, thus precluding its use in the
mitogenesis assay.
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Figure 2 Comparison of PTHRP-R expression and responsiveness to
PTHRP in vector- and receptor-transfected MCF-7 cells. (A) Total RNA
was isolated from MCF-7
VEC and MCF-7
WTR cells, and PTHRP-R
expression was measured by RT–PCR as described in Materials and
Methods. The specific receptor fragment of 571bp is indicated. M¼100bp
size markers, B¼water blank reaction without RNA, C¼control reaction
containing irrelevant RNA and primers. (B) Cells in six-well culture plates
were pretreated for 10min with IBMX (0.5mM) followed by treatment for
a further 10min with vehicle (ethanol, 0.01%; open bars), PTHRP (125nM;
grey bars) or forskolin (1mM; black bars). Extracts were then prepared and
assayed for cAMP content as described in Materials and Methods. The data
represent means7s.e.m. from three independent experiments for each cell
population. Individual assays were performed in triplicate. *Values
significantly different from the corresponding control value (Po0.05;
ANOVA).
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Figure 3 Effect of PTHRP1–34on DNA synthesis in vector and PTHRP-
R-transfected MCF-7 cells. Cells in 24-well culture dishes were incubated in
serum-free medium for 24h prior to treatment for a further 24h with
PTHRP1–34 (25nM; open bars or 125nM; grey bars) or forskolin (100nM;
black bars). [
3H]thymidine (0.25mCiwell
 1) was added for the final 4h,
then cellular uptake of thymidine was measured as described in Materials
and Methods. The data represent the increase (%) in thymidine uptake
relative to unstimulated cells for each cell population and are mean-
s7s.e.m. from three independent experiments for each line. Individual
measurements were performed in triplicate. *Values significantly different
from respective control (Po0.05, ANOVA).
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Figure 4 PTHRP7–34 inhibits DNA synthesis. Cells in 24-well culture
dishes were incubated in serum-free medium for 24h prior to treatment
for a further 24h in a serum-free conditions (SF) or in a medium containing
0.5% serum (0.5%). Cultures received additionally either drug vehicle
(0.0001% acetic acid, black bars) or PTHRP7–34 (1mM, white bars).
[
3H]thymidine (0.25mCiwell
 1) was added for the final 4h, then cellular
uptake of thymidine was measured as described in Materials and Methods.
The data represent means7s.d. from a single experiment assayed in
quadruplicate, which was repeated on another occasion with similar results.
*Values significantly different from PTHRP7–34 treatment (Po0.05,
Student’s t-test).
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mitogenic actions of PTHRP, MCF-7
WTR cells were stimulated with
PTHRP1–34 and, for comparison, EGF and IGF-1, two growth
factors known to act as potent mitogens for MCF-7 cells (Pollak
et al, 1988; Godden et al, 1992). ERK activation was assessed by
immunoblotting with antibodies recognising the dually phosphory-
lated forms of ERK1 and ERK2, which accurately reflects their
activation status (Anderson et al, 1990). As shown in Figure 5A,
PTHRP1–34 induced a small increase in the phosphorylation of
both ERK1 and ERK2. The size of this increase was negligible
compared to that induced by either EGF or IGF-1. However, when
PTHRP was administered prior to EGF or IGF-1, there was a
potentiation of the resultant ERK phosphorylation (Figure 5A). The
degree of potentiation was dependent upon the dose of EGF
administered. Use of suboptimal EGF concentrations revealed the
potentiating action of PTHRP on EGF-induced ERK activation
more clearly (Figure 5B). Conversely, potentiation of EGF-induced
activation of ERKs was also dependent on the concentration of
PTHRP administered (Figure 5C). These results indicate that
PTHRP by itself is a weak activator of the ERK pathway in MCF-7
cells, but that it can boost ERK activation by other growth factors.
We finally tested whether the ERK pathway was required for the
proliferation of MCF-7 cells. Cells were incubated with PD098059,
which blocks the activation of MEK, the protein kinase required for
activation of ERKs (Alessi et al, 1995). As shown in Figure 5D,
although blockade of the ERK pathway almost completely
prevented the increase in [
3H]thymidine induced by 2% serum, it
had no effect on the ability of PTHRP to increase thymidine uptake.
Thus, although PTHRP-induced mitogenesis may occur through an
ERK-independent mechanism, the ability of PTHRP to potentiate
the activation of ERK by EGF and IGF-1, together with the ability of
cells to respond to autocrine PTHRP, could provide one explana-
tion for the increased mitogenic responsiveness and reduced
doubling times of MCF-7 cells overexpressing the PTHRP-R.
DISCUSSION
PTHRP is now well recognised as an important factor in the
development of osteolytic BM from breast cancer. The mechanisms
involved remain to be fully resolved but studies by Guise and
colleagues provide evidence that production of PTHRP forms part
of a vicious cycle involving osteoclast activation followed by the
release of mitogenic growth factors such as IGF-1 from the bone
matrix (Guise, 2000). In this model, PTHRP exerts its actions by
binding to receptors present on osteoblasts, which in response
secrete factors leading to osteoclast activation. The presence or
absence of the PTHRP-R on the tumour cells themselves is unlikely
to exert a major influence in such a process. On the other hand,
PTHRP-R expression may give metastatic breast cancer cells a
selective advantage that allows them to colonise and expand in
secondary sites by permitting autocrine PTHRP signalling. In this
study, we demonstrate that PTHRP-R expression is indeed
maintained in breast cancer BM. Indeed our data suggest that
Table 1 Effect of PTHRP-R expression on mitogenesis
Cell
population
2% Serum-stimulated
thymidine uptake (%)
Doubling
time (h)
Vector 7879 25.0971.04
WT receptor 12279* 20.4871.69*
Cells were placed in serum-free medium for 24h and then stimulated with a medium
containing 2% serum for a further 24h. [
3H]thymidine uptake was measured as
described in Materials and Methods. To measure doubling times, cells were plated in
quadruplicate at low density in a medium containing 2% serum. Cell numbers were
counted every 24h for a total of 96h. The average time taken for each cell
population to double in number was then calculated from the logarithmic phase of
the growth curve. The data are means7s.d. and are derived from three independent
experiments. *A significant difference between MCF-7
VEC and MCF-7
WTR cells
(Po0.05, ANOVA and Student’s t-test).
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Figure 5 PTHRP1–34 potentiates both EGF- and IGF-1-induced
activation of ERK MAP kinases. MCF-7
WTR cells were starved in serum-
free medium overnight. (A) The cells were then treated for 5min with
PTHRP1–34 (125nM) or vehicle followed by nothing, EGF (2nM) or IGF-1
(2nM) for a further 5min. (B) Cells were pretreated with buffer ( PTHRP)
or with PTHRP (125nM) for 5min prior to stimulation with the stated
concentrations of EGF for a further 5min. Lanes labelled C and P represent
samples from control or PTHRP-treated HEK293 cells expressing PTHRP-
R, run as a positive control. (C) Cells were treated with the stated
concentrations of PTHRP1–34 for 5min prior to further stimulation with
0.5nM EGF for 5min. Lysates were prepared and Western blotted for
phospho-ERK1/2 (top panel) as described in Materials and Methods. The
data are representative of experiments carried out on five separate
occasions. (D) MCF7
WTR cells were incubated in serum-free medium for
24h prior to treatment for a further 24h with PTHRP1–34(125nM)o r2 %
serum in the absence (filled bars) or presence (open bars) of 25mM
PD098059. [
3H]thymidine uptake was then measured as described in
Materials and Methods. The data represent the increase (%) in thymidine
uptake relative to cells maintained in serum-free medium are mean-
s7s.e.m. from three independent experiments. *Values significantly
different from respective control (Po0.01, Student’s paired t-test).
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in BM compared to the primary cancer. This suggests that tumour
cells overexpressing the PTHRP-R have a selective survival or
growth advantage in BM. Alternatively, tumour cells may
upregulate PTHRP-R expression as a result of their exposure to
the bone microenvironment. Distinguishing between these possi-
bilities is a goal for future studies.
The presence of the PTHRP-R in metastatic breast tumour cells
clearly indicated that these cells could respond to PTHRP in a
paracrine or autocrine manner. The results of our analyses of
MCF-7 breast cancer cells engineered to express the receptor
provide evidence that PTHRP-R overexpression may be sufficient
to give cells a selective advantage in terms of their proliferative
capacity. We show that this advantage may include not only an
increased capacity to respond to both exogenous and endogenous
PTHRP, but also to heterologous growth factors.
A previous report (Birch et al, 1995) showed that parental MCF-
7 cells responded mitogenically to exogenously applied PTHRP.
The reason why we failed to observe any such effect of PTHRP in
our vector-transfected cells may be because of differences in the
culture conditions used. Nevertheless, our work shows that
mitogenic responsiveness to exogenous PTHRP increases when
the receptor is overexpressed.
Our results also show that the proliferation of MCF-7 cells
overexpressing the PTHRP-R is sustained in part by PTHRP acting
in an autocrine manner. The antiproliferative effects of PTHRP-R
antagonism were greater in cells growing in the presence of serum.
Since PTHRP is not present at detectable levels in normal FCS (CS
and NGA, unpublished data), this suggests that the proliferation of
MCF-7 cells in serum is supported to a greater extent by autocrine
PTHRP. This may be because growth factors present in serum
stimulate the production of endogenous PTHRP. Interestingly,
PTHRP gene expression is reported to be promoted via the Ras-
ERK pathway (Aklilu et al, 2000), and many of the growth factors
present in serum are well known to activate this pathway.
Apart from acting through the PTHRP-R, recent studies have
uncovered an alternative mechanism through which PTHRP can
exert cellular actions. This involves an intracrine pathway through
which newly synthesised PTHRP is directed to the nucleus. The
precise role that this novel pathway plays in controlling cellular
function is still unclear, but it is interesting to note that the
overexpression of PTHRP in MCF-7 cells results in increased
proliferation via an intracrine mechanism (Falzon and Du, 2000).
Intracrine PTHRP signalling required overexpression of PTHRP
indicating that this pathway is unlikely to operate with the
endogenous levels of PTHRP present in our cell system. Never-
theless, it would be interesting to test whether intracrine and
autocrine PTHRP activity coexist in cells with overexpression of
both PTHRP and the receptor.
In addition to conferring increased responsiveness to PTHRP,
our results also show that overexpression of the PTHRP-R
sensitises cells to the mitogenic actions of heterologous growth
factors present in serum. One potential explanation for these
results could involve, as suggested above, an increase in the
synthesis of PTHRP in cells cultured in a serum-containing
medium. Cells expressing the PTHRP-R would show increased
autocrine responsiveness to PTHRP. Our results, showing that
PTHRP-R antagonism is more effective in the presence of serum,
support this conclusion.
An additional explanation for the apparent increased mitogenic
responsiveness of cells expressing the PTHRP-R derives from the
results of our analysis of ERK signalling. We found that PTHRP
indirectly influences signalling through the ERK pathway; while
PTHRP had little effect on its own, it increased the resulting
activation of ERK when cells were stimulated by EGF and IGF-1.
The mechanisms involved remain to be established, although it is
interesting to note that ATP, which also signals via a GPCR,
potentiated EGF signalling in MCF-7 cells (Wagstaff et al, 2000).
Since the ERK pathway appears critical for optimal proliferation in
MCF-7 cells (Hermanto et al, 2000), the potentiation of its
activation by PTHRP may be significant and could provide a
further explanation for the enhanced mitogenesis in cells over-
expressing the PTHRP-R.
Finally, our studies provide some insight into the mechanisms
by which PTHRP induces mitogenesis in MCF-7 cells. Although the
ERK pathway is required for optimal proliferation in MCF-7 cells,
blockade of its activation using the chemical inhibitor PD098059
failed to affect PTHRP-induced mitogenesis, ruling out any
involvement of this pathway in the direct mitogenic effects of
PTHRP.
As shown in many other systems, the PTHRP-R couples via Gs
to adenylyl cyclase and the cAMP signalling pathway (Gardella and
Juppner, 2001). Although we were unable to test directly whether
this pathway mediates the mitogenic effects of PTHRP in MCF-7
cells, the fact that forskolin, a direct activator of adenylyl cyclase,
also promoted mitogenesis indicates that cAMP is mitogenic in
these cells. This appears to contradict previous reports suggesting
that the cAMP signalling system inhibits proliferation in MCF-7
cells (Chen et al, 1998). We believe that this apparent difference
may be explained by the relative strength of the cAMP signal
generated. We have shown previously that fibroblasts can respond
differentially to low/transient vs high/sustained levels of cAMP
(Yarwood et al, 1998). In the present study, low concentrations of
forskolin promoted mitogenesis whereas high concentrations were
inhibitory (RP and NGA, unpublished data). The antiproliferative
effects reported in the study by Chen et al resulted from the
introduction of dominantly active version of Gs into the cells, and
although they did not report the levels of cAMP generated by this
procedure, it is likely that such a manipulation would lead to
sustained cAMP signalling. We therefore contend that PTHRP
promotes mitogenesis in MCF-7 cells by generating transient
increases in cAMP.
To conclude, we have shown that the PTHRP-R is expressed in
breast cancer BM, and thus may mediate autocrine PTHRP
signalling in these lesions. Overexpression of the PTHRP-R in a
breast cancer cell line increases the mitogenic responsiveness of
these cells not only to PTHRP but also to heterologous growth
factors. PTHRP can promote mitogenesis in an autocrine manner
via receptor-mediated increases in cAMP and by sensitising the
ERK signalling pathway to stimulation by other growth factors.
Strategies aimed at blocking PTHRP-R activation may therefore
slow the progression of breast cancer cells in BM.
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